Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn’s Disease Patients Who Failed Anti-tumor Necrosis Factor-α Treatment in Japan: An Observational Study Utilizing Claims Database-Reference-Cited by-同舟云学术

Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Crohn’s Disease Patients Who Failed Anti-tumor Necrosis Factor-α Treatment in Japan: An Observational Study Utilizing Claims Database

Published:2024-02-16 Issue:2 Volume:47 Page:443-448
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biological & Pharmaceutical Bulletin

Author:

Shimazaki Minoru¹,Matsuyama Yutaka²,Koide Daisuke³

Affiliation:

1. Department of Epidemiology and Biostatistics, School of Integrated Health Sciences, Faculty of Medicine, The University of Tokyo

2. Department of Biostatistics, School of Public Health, Graduate School of Medicine, The University of Tokyo

3. Department of Biostatistics & Bioinformatics, Graduate School of Medicine, The University of Tokyo

Publisher

Pharmaceutical Society of Japan

Link

https://www.jstage.jst.go.jp/article/bpb/47/2/47_b23-00847/_pdf

Reference17 articles.

1. 1) Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn’s disease. Nat. Rev. Dis. Primers, 6, 22 (2020).

2. 2) Roda G, Jharap B, Neeraj N, Colombel JF. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin. Transl. Gastroenterol., 7, e135 (2016).

3. 3) Masui S, Yonezawa A, Momo K, Nakagawa S, Itohara K, Imai S, Nakagawa T, Matsubara K. Infliximab treatment persistence among Japanese patients with chronic inflammatory diseases: a retrospective Japanese claims data study. Biol. Pharm. Bull., 45, 323–332 (2022).

4. 4) Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J. Crohns Colitis, 14, 4–22 (2020).

5. 5) Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F, Meyer A. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment. Pharmacol. Ther., 51, 948–957 (2020).